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Summary. The rat-liver carcinogen 4-dimethylaminoazobenzene (Butter Yellow,
DAB) and 12 of its structural analogues have been evaluated in a cell transformation
assay. Eight of these analogues have already been tested for carcinogenicity in rats,
whilst the remaining4 are new or hitherto untested. Benzidineand its3,3'-disulphonic
acid derivative have also been evaluated.
The in vitro results agree with long-term animal data for8 compounds but disagree
in finding DAB-4'-sulphonic acid, 4-trifluoromethyl-DAB and 4-diethylaminoazo-
benzene positive. Possible reasons for these divergencies arediscussed. Itis concluded
that 9-phenylazojulolidine and N-methyl-5-phenylazoindoline have carcinogenic
potential and that 3,5-dimethyl-4-aminoazobenzene and 4-aminoazobenzene-4'-
sulphonic acid are likely to prove non-carcinogenic.
Addition of azobenzene to the in vitro assay medium increases the transforming
potency of DAB 25-fold. It is suggested that it acts as a competitive substrate for one
of the enzymes that detoxify DAB, and that this effect is related to that produced by
norharman.
Sulphonic-acid derivatives of established carcinogens are usually inactive. The
basis ofthis effect has been investigated, and it is suggested that it can operate by two
separate mechanisms.
It has been established that this assay cannot be relied upon to predict the in vivo
potency of a carcinogen.
Consideration has been given to possible changes which could be made to the liver
activation system (the S-9 mix) currently used in in vitro carcinogenicity assays, and
a diagram is presented of the metabolic conversions of acomzpound which might lead
to mutation or tumour formation. This enables the term potential carcinogen to be
accurately defined, and indicates a possible difference between absolute non-carcino-
gens and compounds which fail to produce cancer in vivo.
BUTTER YELLOW (DAB; I), together
with many of its substituted derivatives
or functional analogues (U.S. P.H.S. Sur-
vey ofCompounds which have been tested
for carcinogenic activity; Arcos andArgus,
1974), form one of the most widely evalu-
ated series of carcinogens, and they there-
fore present an interesting series in which
to compare the findings of long-term ani-
mal carcinogenicity experiments with the
predictions of possible carcinogenicity
made by in vitro assays.
An in vitro carcinogenicity assay is Usu-
ally judged by its ability to detect both
carcinogens and non-carcinogens selected
from a wide variety of structural classes
(McCann et al., 1975, Sugimura et al., 1976;
Purchase et al., 1976, 1978) and although
this is a necessary first step in the valida-
tion of a test it is not likely to define its
strengths and weaknesses, especially if
these properties are chemical-class related.
The series of compounds based on DAB
was selected for study because it was
thought likely that some of the problems
that might be expected to accompany theEVALUATION OF DERIVATIVES OF BUTTER YELLOW
extrapolation ofin vitro test predictions to
the situation in vivo might thereby become
apparent.
Butter Yellow was first identified as a
carcinogen by Japanese workers in 1937
(Kinosita, 1937, and reviewed by Arcos
and Argus, 1974) but initial attempts in
America to repeat these observations were
unsuccessful. This divergence of results
was subsequently shown to be due to dif-
ferences in the rat diets used in the two
countries. By employing a polished rice
(riboflavin-deficient) diet, the Japanese
workers had unwittingly reduced the levels
of azo-reductase enzymes (which are ribo-
flavin-dependent) in the liver of the test
animals. These enzymes have since been
shown to be partly responsible for the de-
activation of DAB; therefore, by reducing
their levels, the Japanese workers had
potentiated DAB-mediated tumour pro-
duction. (This sequence ofevents has been
reviewed in detail by Arcos and Argus,
1974.) A corollary to the above is that, had
DAB been tested only under normal
dietary conditions, it would have been re-
corded as a non-carcinogen. It could there-
fore be anticipated that the enzyme profile
of the rat-liver metabolic system (the S-9
mix) used in an in vitro test would be both
diet-dependent and critical in determining
the response given by that test for DAB
and its analogues. The second area of un-
certainty and interest presented by these
compounds flows from the fact that most
of the carcinogenicity data available for
analogues of DAB were generated by a
standard test procedure which was limited
by the restrictions that often only the
liver of exposed animals was studied, and
that most of the experiments were ter-
minated between 9 and 11 months. None-
theless, a tendency to regard such results
as either clearly positive or negative has
inevitably developed. These facts indicate
that the results of an in vitro test might
lead to a different conclusion regarding the
possible carcinogenicity of an analogue of
DAB than that indicated by the original
animal study. It may be too simple to dis-
miss any such divergencies asfalse in vitro
predictions; in fact it is suggested in this
paper that the results of an appropriately
controlled in vitro test can assist in the
interpretation of an imperfect in vivo
study.
The first step in the present study was to
select the most appropriate test for this
particular series of compounds from those
which were available to us, namely, the
salmonella reverse mutation assay ofAmes
et al. (1975) and the cell transformation
assay of Styles (1977). Whilst DAB can
produce a positive effect intheAmesassay,
this response cannot be relied upon (Ames
et al., 1973; McCann et al., 1975; Purchase
et al., 1978; Ashby and Purchase, 1977;
Nagao et al., 1977). Such uncertainty is
important in a study such as the present
one. A negative result for an analogue of
DAB would be meaningless in the presence
of a negative result for DAB itself, a self-
imposed restraint which has led to many
studies having to be repeated in our
laboratory with other series of compounds.
In contrast to the performance oftheAmes
assay, the Styles assay consistently found
DAB positive in preliminary experiments.
Therefore, by applying the test selection
criteria described earlier (Ashby et al.,
1977) we adopted the cell transformation
assay for this study.
All experiments with this assay were
conducted using DAB as the chemical-
class-positive control and with 3-methyl-
4-dimethylaminoazobenzene (3-methyl-
DAB, II) as negative control (Ashby and
Purchase, 1977; for a discussion of this
selection see later). Elevencompoundsthat
had previously been evaluated in rats for
carcinogenicity [Compounds I, II, VI, VII,
X, XI, XII, XIII, XIV and XVI (see
Chart)] were tested, together with 4 pre-
viously unevaluated derivatives of DAB
[compounds VIII, IX, XVII and XVIII
(see Chart)].
MATERIALS AND METHODS
Chemicals
The preparations of N-methyl-5-phenyl-
azoindoline (IX) and benzidine-3,3'-disul-
phonic acid (XI) are here described in detail;
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the preparation of the remaining compounds
is described briefly. The C, H and N content
of each compound has been determined and,
unless stated otherwise, is within 0.3% ofthe
theoretical values. In addition, the NMR, IR
and mass spectrum of each compound has
been determined and is consistent with the
structures shown (any exceptions are shown
in square brackets). No significant impurities
in any ofthe test compounds were detected by
any ofthe above methods, or by TLC exami-
nation. NMR spectra were recorded either at
60 MHz using a Perkin-Elmer R-12 or Varian
A-60 spectrometer, at 100 MHz using a Varian
HA 100 (D) spectrometer, or at 90 MHz by
Fourier transformation using a Bruker HX
90E spectrometer. Mass spectra were de-
termined using either an AEI MS9 or an MS
902 instrument (M+ implies detection of the
required mass ion).
4-Dimethylaminoazobenzene (Butter Yellow,
DAB, I).-Supplied by B.D.H. Ltd, Dorset,
and was further purified by recrystallization
from cyclohexane in the presence ofcharcoal,
m.p. 116°C (Berju, 1884: m.p. 117°C).
3-Methyl-4-dimethylaminoazobenzene (3-
methyl-DAB, II).-Prepared by condensa-
tion of nitrosobenzene with 3-methyl-4-
dimethylaminoaniline as reported by Van
Loon et al. (1960). Chromatography on florisil,
using chloroform as eluent, produced a red
oil (70%) which could not be induced to
crystallize.
Azobenzene (VI).-Purchased from B.D.H.
Ltd, and appeared to be pure by all of the
analytical techniques used, m.p. 67-68°C
(Hartley, 1938: m.p. 68°C).
3,5 - Dimethyl - 4 - dimethylaminoazobenzene
(VII).-Prepared by methylation of 3,5-
dimethyl-4-aminoazobenzene (XVII) in
Carius tubes at 75°C for 20 h using methyl
iodide and sodium carbonate in a mixture of
methanol and water as described by Horner
and Muller (1956). Primary and secondary
amine contaminants were removed by con-
version to their acetyl derivatives, and the
product purified by chromatography on silica
gel, eluting with chloroform. The material so
obtained was converted to its hydrochloride
and crystallized from acetone (98%) m.p.
163-64°C (Horner and Muller, 1956: m.p.
151°C). [Theory for C16H20N3Cl: C, 66-3; H,
6-9; N, 14-5. Found: C, 65-8; H, 7-0; N,
14.3%.]
9-Phenylazojulolidine (VIII).-Prepared by
the method of Castelino and Hallas (1971)
except that after removal of residual amines
by steam distillation the product was puri-
fied by chromatography on florisil, eluting
with toluene. After recrystallization from
methanol containing a little petroleum ether
(b.p. 60-80°C) the pure product had an m.p.
of 83-84°C (Castelino and Hallas, 1971; m.p.
80-820C).
N-Methyl-5-phenylazoindoline (IX).-Ani-
line was diazotized (Conant et al., 1941) in the
presence of 4 equivalents of HCI, and the
diazonium solution added slowly toN-methyl-
indoline in 4 equivalents of aqueous sodium
acetate solution. After stirring for 3 h the
orange-coloured precipitate was collected,
washed with water and dried. It was purified
by chromatography on florisil, eluting with
chloroform, and was finally recrystallized
from petroleum-ether (b.p. 60-80°C) to give
red prisms (46%), m.p. 91-92°C. As this is a
new compound, its full analytical data have
beenrecorded. TheoreticalforC15H15N3 (237):
C, 75-9; H, 6-3; N, 17-7. Found: C, 75-8; H,
6-4; N, 17.4%, M+ 237; NMR (60 MHz,
CDC13) 6-4 parts/106 (d) 1 H, H-7; 7.3-7.95
parts/106 (m) 7 H, remainder of aromatics;
2-78 parts/106 (s) 3H, N-methyl; 2-78-3-6
parts/106 (m) 4H, -CH2CH2-. Literature
precedent for the electrophilic substitution of
N-methylindoline taking place in the 5-posi-
tion is given by Terent'ev and Preobrazhens-
kaya (1959) and is confirmed in this case by
the presence in the NMR spectrum of the
signal for H-7 (which would be expected to
be the highest field aromatic proton) showing
ortho-coupling.
4 - Dimethylaminoazobenzene - 4' - sulphonic
acid, sodium salt (methyl orange, X).-Ob-
tained from B.D.H. Ltd and recrystallized
from water in order to attain satisfactory
analytical purity.
Benzidine-3,3'-disulphonic acid (XI).-Pre-
pared by a modification of the method of
Skrowaczewska (1953). Benzidine (11 g) and
concentrated sulphuric acid (6-6 ml) were
mixed together as thoroughly as possible be-
fore the start of the exothermic reaction,
which was then allowed to proceed. When the
reaction had subsided, diphenyl sulphone (20
g) was added. The vessel was evacuated
(water-pump pressure) and heated for 7 h in
an oil bath at 250°C. The mixture was allowed
to cool and the solid mass broken up and
finelygroundinamortar. Thesolidwastreated
with excess dilute aqueous NaOH solution
and filtered. The residual solid was washed
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on the filter with NaOH solution and the com-
bined filtrates acidified with dilute HCR. The
precipitated product was collected, resuspend-
ed in water, filtered anddried (92%). The grey
solid (m.p.>340'C) was soluble in cold DMSO
but only sparingly soluble in other organic
solvents. TLC (Merck silica gel GF, developed
either in methanol or in chloroform/methanol
9:1) showed a less polar impurity at a level
which was just detectable by u/v light. Theo-
retical for C12H12N206S2 (344): C, 41-9; H,
3-5; N, 8-1. Found: C, 41-9; H, 3-7; N, 841%.
At 310°C no M+ 344 was observed, but a weak
265 (344-SO3) and a strong 184 (265-SO3) were
seen. NMR (100 MHz, DMSOd6) 7-2-7-9parts/
106 (m) aromatic; 8-55 parts/106 (s), NH2,
S03H.
Benzidine (X1I).-Supplied by B.D.H.
Ltd and was found to be ofsatisfactory purity
as received, m.p. 128-29°C (Merz andStrasser,
1899; m.p. 128°C).
4 - Dimethylamino - 4' - trifluoromethylazo-
benzene (XIII).-Obtained by diazonium
coupling of 4-trifluoromethylaniline with
N,N-dimethylaniline inthe presence ofsodium
acetate. The product was collected, washed
with water, dried, recrystallized from ethanol
(m.p. 166-67°C) and then from benzene to
yield golden-yellow plates m.p. 167-68°C
(Isaks and Jaffe, 1964: m.p. 178-178-50C).
Despite the melting point remaining below
that previously reported, this material ap-
peared pure when judged by all other criteria.
Further, itsNMR spectrum clearly established
para-para substitution.
4-Diethylaminoazobenzene (XIV).-Pre-
pared by the method of Gnehm and Bauer
(1905). After recrystallization from ethanol
containing a little water, the product (44%)
had an m.p. of 97-98°C (Gnehm and Bauer,
1905: m.p. 98-99°C). [TheoreticalforC16H1qN3
hemihydrate: C, 73-3; H, 7-6; N, 16-0. Found:
C, 73-0; H, 7-5; N, 16-0%.]
4 - Diethylamino - 4' - ethylazobenzene (XV).
-Prepared as described by Arcos and
Simon (1962). After recrystallization from
ethanol the product had an m.p. of 173-74°C
(Arcos and Simon, 1962: m.p. 173-5-74-5°C).
4-Aminoazobenzene (XVI).-Supplied by
I.C.I. Pharmaceuticals Division, Alderley
Park, Macclesfield, Cheshire, and was further
purified by recrystallization from toluene to
give yellow needles of m.p. 125-26°C (Witt
and Thomas, 1883: m.p. 125-26°C).
3,5-Dimethyl-4-aminoazobenzene (XVII).-
Prepared by the method of Horner and
Muller (1956) but the product was isolated as
the violet-coloured hydrochloride, and re-
crystallized from n-butanol containing a few
drops of 11 N HCI (20%) m.p. 196-97°C (no
literature on m.p. available).
4 - Aminoazobenzene - 4' - sulphonic acid
(XVIII).-Supplied by I.C.I. Pharmaceuti-
cals Division. It was found pure by all
of the analytical techniques used and was
tested as received. [Theoretical for C12H11-
N303S+1±25H20: C, 4841; H, 4-5; N, 14-0.
Found: C, 48-3; H, 4-3; N, 13.7%.]
Cell-transformation test.-The methods em-
ployed when testing a compound for potential
carcinogenicity using growth of mammalian
cells in semi-solid agar have been described in
detail (Styles, 1977). A positive result is re-
corded when the transformation frequency
per 106 survivors at the LD50 exceeds 5 X the
control frequency. The cells used in this study
were BHK21/C13, which had a spontaneous
transformation frequency of50/106 survivors,
or 10/106 survivors in a later clone. The sol-
vent used in all experiments was DMSO
(B.D.H. Chemicals Ltd, Poole, Dorset) and
allexperimentswereconductedinthepresence
of Aroclor 1254-induced rat liver S-9 mix.
RESULTS
Transformation frequencies (corrected
to a theoretical LDo) and cell survivals
obtained after treatment of the cells with
the following compounds listed below are
shown in Fig. 1: 4-dimethylaminoazoben-
zene (I) (a, average of 7 experiments and
b, using the new clone), 3-methyl-4-di-
methylaminoazobenzene (II) (c, average
of 3 experiments and d, using the new
clone), azobenzene (VI) (e, using the new
clone), a mixture of 4-dimethylamino-
azobenzene (I) and azobenzene (VI), show-
ing concentration ofeach compound mixed
(f), 3,5-dimethyl-4-dimethylaminoazoben-
zene (VII) (g), 9-phenylazojulolidine (VIII)
(h), N-methyl-5-phenylazoindoline (IX)
(i), 4-dimethylaminoazobenzene-4'-sulpho-
nic acid, sodium salt (methyl orange)
(X) (j), benzidine-3,3'-disulphonic acid
(XI) (k), benzidine (XII) (1, average of 5
experiments), 4-dimethylamino-4'-trifluo-
romethylazobenzene (XIII) (m), 4-diethyl-
aminoazobenzene (XIV) (n), 4-diethyl-
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amino-4'-ethylazobenzene (XV) (o), 4-
aminoazobenzene (XVI) (p), 3,5-dimethyl-
4-aminoazobenzene (XVII) (q) and 4-
aminoazobenzene - 4' - sulphonic acid
(XVIII) (r). The experiments were con-
ducted in small groups using duplicate
plates at each dose level, and on each occa-
sion 4-dimethylaminoazobenzene (I) and
its 3-methyl analogue (II) were used as the
appropriate chemical-class-positive and
-negative controls (Ashby and Purchase,
1977). In addition, all experiments were
conducted in the presence of DMSO as a
second negative control. Compounds I,
VIII, IX, X, XII, XIII, XIV, XV, XVI
and XVIII gave a positive response whilst
compounds II, VI, VII, XI and XVII gave
a negative response. Compounds I, II, VI
and a mixture of compound I and VI were
tested using a later clone with a sponta-
neous transformation frequency of 10. The
results obtained with this clone (Figs lb,
d, e and f) are therefore scored as positive
iftransformation exceeds 50transformants
per 106 survivors (reflected in a change in
the position of the horizontal dotted line
in these figures as compared with the other
figures).
DISCUSSION
The carcinogenic activation of DAB has
been suggested as proceeding via oxidative
mono-demethylation accompanied by N-
oxidation, yielding the N-hydroxy deriva-
tive (III) of 4-methylaminoazobenzene
(Scheme) (Lin et al., 1975, reviewed by
Arcos and Argus, 1974). Subsequent esteri-
fication of this N-hydroxy derivative is
thought to lead to the formation of an
electrophilic species (formally suggested to
be a nitrenium ion (Lin et al., 1975)) which
reacts with guanosine in the 8-position
(and perhaps at other sites on DNA).
It has been suggested that intracellular
transport of this activated species occurs
via a receptor protein (Mainigi and Sorof,
1977). The active ester formed from com-
pounds such as III has generally been
assumed to be the sulphate derivative, but
this idea has recently been questioned in
the case ofthe metabolic activation of the
carcinogen 2-acetylaminofluorene. In this
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case, the formation of an acetate ester has
been postulated (Yamamoto et al., 1968;
Weisburger et al., 1972; Yamamoto et al.,
1973) and this might also apply to other
carcinogens such as DAB.
There is also evidence for the existence
of two competitive, metabolic detoxifica-
tion routes for DAB and its derivatives.
The first involves cleavage of the com-
pound at the azo-linkage via azoreductase
enzymes, yielding, in the case ofDAB, the
anilines IV and V. The second involves
ring hydroxylation followed by conjuga-
tion (Lin et al., 1974; Commoner et al.,
1974; Topham and Westrop, 1964;
AVestrop and Topham, 1966) (Scheme).
Evidence that the azoreductase pathway
results in the detoxification of DAB is
afforded by the observations that both IV
and V are non-carcinogenic under the same
test conditions as those in which DAB is
carcinogenic (Miller and Baumann, 1945;
Miller and Miller, 1948; Miller et al., 1957),
and by the observation that rats treated
with DAB develop a higher incidence of
liver tumours when the level of their liver
azoreductase enzymes is artificially de-
pressed by diet manipulation (Miller et al.,
1941; Miner et al., 1943; Miller, 1947;
Kensler, 1949).
Clearly, variations in the relative contri-
bution made by these 3 metabolic path-
ways could give rise to variations in both
the in vivo and in vitro responses to DAB
and its analogues. In particular, under
conditions where the rate of azo-reductive
or ring-oxidative deactivation of DAB
critically exceeded the rate of whole-
molecule N-oxidation, a reduced, or per-
haps abolished, biological response might
be expected. The early problems en-
countered when attempting to obtain a
reproducible carcinogenic effect for DAB
(reviewed by Arcos and Argus, 1974) and
the current problems in obtaining a repro-
ducible response for this compound in the
salmonella assay may therefore be related.
The reproducibility ofthe cell transforma-
tion assay response for DAB (I) (Fig. la
and b) may be due to augmentation of the
metabolie activity of the rat liver 8-9 mix
by hamster and other rodent cells' innate
capacity for oxidative metabolism (New-
bold et al., 1977; Heidelberger, 1976).
Nonetheless, these cells are incapable of
completing the activation of DAB by
themselves, as evidenced by the negative
response produced bythiscompoundeither
in the absence ofrat liver S-9 mix or in the
presence of uninduced liver homogenate.
These negative results may be due to an
inability to esterify any N-hydroxy inter-
mediate (III) that might be formed by the
cells (cell toxicity is observed). Alterna-
tively, stabilization of metabolically acti-
vated DAB by appropriate receptor
proteins (Mainigi and Sorof, 1977) may be
occurring in the BHK cells but not in the
salmonella, thereby increasing the relative
half-life and selective reactivity of such
species in the cell-based test.
In an attempt to demonstrate the im-
portance of metabolic detoxification path-
ways to the response given by an in vitro
test, we tested DAB in the cell-transforma-
tion assay in the presence of azobenzene
(VI). This material, whilst being non-
carcinogenic to rats (Spitz et al., 1950) and
negative in the present assay (Fig. le) was
intended as a substrate for both the C-
hydroxylase and azoreductase enzymes of
the S-9 mix. It was expected that by test-
ing DAB in the presence ofazobenzene the
contribution made by the critical activa-
tion pathway for DAB would be increased
with respect to those pathways acting
against the production of a DNA-active
species. The enhanced response obtained
is shown in Fig. 1(f), and serves to under-
line the variability in in vitro test response
to be expected with changes in the S-9 mix
or overall in vitro metabolism (Ashby and
Styles 1978a, b). These effectscloselyparal-
lel those produced by norharman with
DAB in the Ames assay (Nagao et al.,
1977) and those produced by 4'ethylation
of DAB, to be discussed later. These ob-
servations may also cast some light on the
fact that most derivatives ofDAB carrying
a substituent ortho to the azo bridge are
non-carcinogenic (reviewed by Arcos and
Argus, 1974). In a related series of azo-
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benzene alkylating agents, Ross and War-
wick (1955) have shown that those deriva-
tives bearing substituents ortho to the azo
linkage undergo accelerated reductive
cleavage of the azo group. It may there-
fore be an increased rate of azoreductase-
mediated detoxification which renders the
corresponding analogues of DAB non-
carcinogenic. The potential of these deri-
vatives of DAB to cause cancer may still
be present, but their ability to express this
potential may have been metabolically
limited to zero. A major exception to this
hypothesis is provided by 2',3'-dimethyl-
4-dimethylaminoazobenzene, which is a
potent liver carcinogen. The inexplicabi-
lity of this high activity has been com-
mented on already (Arcos and Argus, 1974,
p. 160) but can, nonetheless, perhaps be
explained in the light of the above con-
siderations. With this compound, acceler-
ated reductive cleavage will lead to the
formation in the liver of 2,3-dimethyl-
aniline. This compound, although of un-
known carcinogenicity, is likely itself to
be a liver carcinogen (Russfield et al.,
1973). Therefore in this case cleavage of
the azo link may lead to the in situ forma-
tion of another liver carcinogen.
The above reasoning leads to the hypo-
thesis that many compounds may be
chemically equipped, and theoretically
able to cause cancer under individually
optimized metabolic circumstances, but
only a proportion of these may be capable
of actually inducing tumours under the
metabolic conditions ofan in vivo study. If
this is true, a dilemma is posed by the
possibility that in vitro carcinogenicity
assays may sometimes detect the potential
rather than the ability in vivo ofa chemical
to cause cancer. As the number of com-
pounds in the former category may be sig-
nificantly larger than those in the latter,
some attention should be given to what is
inferred from the results of such in vitro
assays. In particular, the following ques-
tion should be answered: are carcinogen-
screening programmes designed to protect
the majority of a population from expo-
sure to easily demonstrable animal car-
cinogens, or are they also to be used to
protect all metabolically idiosyncratic
minorities of a population from each and
every possible carcinogen? (The metabolic
differences of these subgroups may be en-
vironmentally or genetically determined.)
The existence of such sub-groups is prob-
ably evidenced by the non-uniform in-
cidence of tumours generally observed
when either animals orhumansareexposed
to chemical carcinogens. The answer to the
above question will determine whether the
enzyme profile ofthe S-9 liverfraction used
in in vitro assays should be regulated, as
far as is possible, to that encountered by
a chemical in the liver of an average man,
or ifit is to be individually optimized, per-
haps as a "cocktail" of individually puri-
fied enzymes, to give the maximum chance
of obtaining a positive response for each
compound. The above considerations are
shown diagrammatically in Fig. 2, which
enables the term potential carcinogen to be
accurately defined, and which indicates
that there are probably 2 classes of non-
carcinogens recorded in the literature. The
first, a group of absolute non-carcinogens
and the second, compounds which are
potential carcinogens but which have so far
given only a non-carcinogenic effect in vivo.
Chemicals within the latter group could
possibly be induced to produce tumours
by the appropriate choice ofanimal species
and strain, or diet etc. These arguments
cast doubt on the historical concept of
absolute carcinogens and non-carcinogens,
but this should not be abandoned too
readily, at least not until an alternative
ground-rock can be found upon which to
base decisions concerning the potential
human hazard presented by exposure to
a given chemical.
3,5-Dimethyl-DAB (VII) was first syn-
thesized by Horner and Muller (1956) as a
possible non-carcinogenic analogueofDAB
(I). In this compound, the two ortho me-
thyl groups interact sterically with the 4-
dimethylamino function and thereby pre-
vent the nitrogen base-pair of electrons
from conjugating with the aromatic ring
system. This interaction is amply demon-
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FIe. 2. Diagrammatic representation of the moderating effects produced by competitive metabolic
pathways on the carcinogenicity of a compound. The starting compound is assumed not to be a
direct-acting carcinogen. In such cases the compound would be placed directly in the central box.
The position of the indlicator in each dial could affect both the in vivo and in vitro response given by
a compound. The exact indicator positions will be influenced by the (liet, sex, age, species and strain
of the test animal, and (lose levels employed in an in vivo study, the method of induction, prepara-
tion and storage ofthe liver S-9 mix usedl in an it vitro assay and the presence ofcompetitive enzyme
substrates, both in vi'io andl in vitro.
strated by reference to molecular models
and by the colour and u.v. spectrum ofVII
when compared with DAB (Horner and
Muller, 1956). Horner and Muller anti-
cipated that this steric restraint, which
effectively transforms VII into an ana-
logue of azobenzene (VI) rather than of
DAB (I), would also convert it into a non-
carcinogen. The carcinogenicity experi-
ment conducted on VII by Druckrey
(Horner and Muller, 1956) confirms this
prediction, as does the negative response
it gave in the cell-transformation assay
(Fig. 1g). This rationale would apply
equally to 3-methyl-DAB (II), the pres-
ence of a second ortho methyl group being
redundant to the above steric explanation,
and again the transformation assay (Fig.
lc and d) and 2 carcinogenicity experi-
ments in rats confirm this prediction (see
later). The inactivity of compounds II and
VII is probably due to the abolition (or
critical reduction) of oxidative demethyla-
tion by steric or electronic factors. The
carcinogenicity of 3-methyl-4-methyl-
aminoazobenzene (XIX; Miller and Miller,
1948), the sterically unrestricted mono-
demethylation product of (II), indicates
that this "block" occurs early in the meta-
bolic sequence. An indication that the
sterically enforced deconjugation of the
substituent nitrogen atom from the aro-
matic system is responsible for the in-
activity of both II and VII (Fig. 3) is
afforded by the observations that both the
julolidine derivative (VIII) and the indo-
line derivative (IX) are positive in the
transformation assay (Figs. lh and i, re-
spectively). Compound VIII represents a
close derivative ofCompound VII in which
planarity between the nitrogen substituent
and the aromatic system has beenrestored,
and with it the ability ofthe nitrogen lone-
pair of electrons to conjugate with the
aromatic system (Fig. 3). The indoline (IX)
is a similar analogue ofCompound II. Both
the julolidine derivative (VIII) and the
indoline derivative (IX) must therefore be
regarded as potentially carcinogenic com-
pounds. The in vitro activity of the juloli-
dine derivative (VIII) is at variance with
the idea that, in order to show activity,
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FIG. 3. Diagrammatic representation of the effect of steric hindrance of the -NMe2 group of DAB-
related compounds. The small arrows represent overlapping, or orthogonal pi electrons. Only two
pi electrons are shown on the azobenzene part ofthe molecule, although each C and N atom possesses
overlapping and conjugated pi electrons.
derivatives of DAB should have at least
one unsubstituted ortho position (Miller et
al., 1957).
Before leaving this topic, it must be
observed that 3-methyl-DAB (II) has, on
2 separate occasions, been described as a
non-carcinogen by Miller and Miller (1948;
1953). Nonetheless, in a later study (Miller
et al., 1957) the appearance of 2 benign
hepatomas at I1 months (it is not stated
whether they were both in the same ani-
mal) led to the re-classification of this
compound as a weak carcinogen (<1 on a
scale where DAB= 6). In the light of the
above considerations it is possible that
these two hepatomas represented an ab-
normal background incidence, especially
as there was no indication of cirrhosis, a
feature which usually accompanies DAB-
type carcinogenicity. Alternatively, ifthey
were chemicallv mediated and therefore
significant, the above rationale and in
vitro assay results would have to be associ-
ated with a marked reduction in, rather
than an abolition of, carcinogenic activity.
This is not, of course, the end-point that
such in vitro assays and chemical explana-
tions are currently assumed to respond to,
so that an early and detailed in vivo study
of this compound is desirable. (A histo-
chemical study of the carcinogen 3'-
methyl - 4 - dimethylaminoazobenzene
(Hadjiolov, 1963) has been incorrectly ab-
stracted by the U.S. P.H.S. Survey of
compounds which have been tested for car-
cinogenic activity as the 3-methyl analogue
(II), which therefore appears as a carcino-
gen. Reference to the French abstract of
the original paper (Hadjiolov, 1963) con-
firms this error.)
4-Dimethylaminoazobenzene-4'-sulpho-
nic acid (methyl orange) (X) has been
shown to be non-carcinogenic to rats in a
comparatively detailed study (Niepar et al.,
1956). The positive response given by this
compound in the transformation assay
(Fig. lj) therefore represents a false-posi-
tive result, especially as this material is
reported to give a negative response in the
Ames assay (McCann et al., 1975). (The
significance ofthis negative result is none-
theless weakened by an earlier report that
the parent carcinogen DAB (I) was also
negative in this assay in the same labora-
tory (Ames et al., 1973).) There are at least
2 possible explanations for the non-carci-
46
t t CH
/ 3
N=N N
\CH3
N=N-
I
N=N NEVALUATION OF DERIVATIVES OF BUTTER YELLOW
nogenicity of X. First, it could be sug-
gested that the addition ofa sulphonic-acid
group to DAB (I) will reduce its lipid
solubility and thereby prevent, or inhibit,
its transport in vivo to critical intracellular
sites. This explanation would be consistent
with X giving a positive response in vitro.
Second, it is possible that the marked
negative inductive effect exerted by the
sulphonic-acid group might critically affect
both the electronic resonance of the NMe2
group with the aromatic system and the
metabolism of the molecule, which would
lead to X being inactive both in vivo or in
vitro. The positive response given by X in
the transformation assay therefore favours
the former explanation. To pursue this
point, we tested the non-carcinogenic
(Spitz et al., 1950) disulphonic acid deriva-
tive XI of the established carcinogen ben-
zidine (XII; Spitz et al., 1950). With this
derivative, the spacial proximity of the
sulphonic-acid groups to the amino groups
would be expected to exert such a marked
electronic, steric and hydrogen-binding
effect on them that they would be incap-
able of undergoing or effectively complet-
ing the required oxidative activation. This
sulphonic-acid derivative would therefore
be expected to produce negative effects
both in vivo and in vitro, and such were
observed (Fig. 1k; positive response for
benzidine Fig. 11). The positive transfor-
mation result recorded for methyl orange
(X) remains a "false" prediction of in vivo
carcinogenic activity, but it indicates that
this inactivity in vivo is less firmly founded
than is that of the benzidine derivative
(XI). 4-Dimethylamino-4'-trifluoromethyl-
azobenzene (XIII) represents a "hybrid"
of DAB (I) and methyl orange (X) in
which the lipophilic nature of DAB has
been retained, but where the -CF3 group
provides a strong negative inductive effect,
similar to that exerted by the 803H
group of methyl orange. It was therefore
anticipated that this derivative would pro-
duce a positive response in the transforma-
tion assay, which it did (Fig. 1m). This
response possibly represents a further in-
correct in vitro prediction of in vivo acti-
4
vity, as compound XIII was non-carcino-
genic to 11 rats after a 10-months' study
(Miller et al., 1949). This level of negative
in vivo data is insufficient to classify as
false the positive response of the trans-
formation assay and indicates that XII
might show carcinogenic effects in rats if
a larger and longer carcinogenicity study
were to be undertaken on this compound.
Whilst attempts are being made
throughout this discussion to rationalize
any divergences between in vivo and in
vitro results, it is clear that the potency of
a chemical as a transforming agent in this
assay cannot be relied upon to predict its
potency as a carcinogen. In particular,
compare the response for DAB (Fig. la)
with that for its 4-trifluoromethyl deriva-
tive XIII (Fig. lm). The carcinogenic
potency of the latter is 0 on a scale where
DAB is 6 (Miller et al., 1949), whilst the in
vitro transformation potencies for these
compounds differ by a factor of 8 in the
opposite direction (see also Ashby and
Styles, 1978a).
A somewhat similar situation to the
above was encountered with the NEt2 ana-
logue of DAB, 4-diethylaminoazobenzene
(XIV)andits4'-ethylderivativeXV.Whilst
the latter compound is carcinogenic to rats
(Arcos and Simon, 1962) and is positive in
the present in vitro assay (Fig. lo), XIV
is reported to be non-carcinogenic (Sugiura
et al., 1945; Miller and Miller, 1948), yet is
also positive in this assay (Fig. in). If a
fundamental principle were involved in the
non-carcinogenicity of the N-diethyl ana-
logue XIV, it would not be expected that
the apparently trivial substitution of a 4'-
ethyl group, giving XV, wouldre-introduce
carcinogenic activity. The rat studies
which defined 4-diethylaminoazobenzene
as non-carcinogenic employed only 10 rats
each, and again cannot therefore be re-
garded as definitive. This compound is re-
ported to give a negative response in the
Ames assay (McCann et al., 1975) but the
comments made earlier in connection with
the Ames response for methyl orange (X)
apply equally to this result. Again, an
apparently false prediction of in vivo acti-
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vity has been made by this in vitro assay,
and similarly we consider it very probable
that if a more thorough in vivo evaluation
of XIV were undertaken, carcinogenic
properties would be revealed.
Alternatively, it is possible that the
initial mono-de-ethylation of XIV may
occur at a slower rate than the mono-
demethylation of DAB. This could result
in the detoxification routes playing a more
significant part in the overall metabolism
of XIV than they do in the case of DAB.
By blocking one of these pathways, that
ofpara-hydroxylation, by a 4'-ethyl group
(giving XV), a restoration ofthe necessary
balance between activation and deactiva-
tion may have occurred, leading to tumour
formation. Certainly, substitution of DAB
with an ethyl group in the 4'-position
greatly enhances its carcinogenicity (Miller
et al., 1957), thereby simulating the nor-
harman effects referred to earlier.
4-Aminoazobenzene (XVI) is a much
weaker liver carcinogen than DAB (Kirby,
1946; Kirby and Reacock, 1-947) and it
gives a positive response in the Stylesassay
(Fig. lp). The 3,5-dimethyl analogue of
4-aminoazobenzene (XVII) was negative
in the in vitro assay (Fig. lq), whilst the
4'-sulphonic-acid derivative (XVIII) was
positive (Fig. Ir). Although there are no
in vivo data available for either of these
compounds, the in vitro results obtained
are in apparent agreement with those ob-
tained for the corresponding dimethyl-
amino derivatives (VII) and (X) respect-
ively. It could therefore be expected that
both these derivatives would follow the in
vivo pattern observed for the correspond-
ing derivatives of DAB, namely that both
will prove non-carcinogenic.
Three main points emerge from this
study. The first is that theoretical and
structural considerations, linked to an in
vitro carcinogenicity assay, can suggest
which structural analogues of a carcino-
gen are likely to prove carcinogenic and
which are not. Working within a chemical
class in this way probably represents the
most accurate method of priority setting
for future in vivo carcinogenicity studies.
Secondly, for the forseeable future, the
results of in vitro assays will have to be
calibrated by reference to the available in
vivo carcinogenicity data, which will pre-
sent interpretational problems due to the
variability of the latter. Therefore, as the
present study has demonstrated, the situa-
tion will frequently arise where two dif-
ferent in vitro tests come to a different
conclusion about the potential carcino-
genicity of a compound, a situation which
will be incapable of resolution due to the
inadequacy of the available in vivo data
for that compound. For example, at pre-
sent the negative Ames test recorded for
the NEt2 analogue (XIV) of DAB
(McCann et al., 1975) has apparently
anticipated correctly the outcome of the
initial rat study on this compound. None-
theless, were this material to be evaluated
in vivo in the detail accorded to saccharin
(reviewed by Ashby et al., 1978), the posi-
tive cell-transformation assay prediction
might well be vindicated. Finally, it has
been shown that imposed changes in the
overall metabolism of a compound can
dramatically influence the biological re-
sponse that compound elicits both in vivo
and in vitro. Attention should therefore be
given to the question of what the liver
activation systems used in in vitro car-
cinogenicity assays are meant to be
simulating.
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given by Neville Pritchard, Sue Rae and Barbara
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